Long Term Discontinuation Of Eltrombopag After Remission In Primary Immune Thrombocytopenia: 8-Year Follow-Up Data From 15 Spanish Centers

Tomas Jose Gonzalez-Lopez,Fernando Fernandez-Fuertes,Maria Cristina Pascual Izquierdo,Isabel Caparros,Silvia Bernat,Carmen Pastoriza,Maria Paz Martínez-Badas,Pável E Olivera,Gonzalo Caballero,Jose Angel Hernandez-Rivas,Daniel Martínez-Carballeira, Inmaculada Soto Ortega,Gloria Perez Segura, Isabel Regalado,Blanca Sánchez-González,Isidro Jarque,Luis Javier garcia Frade,Miguel A. Sanz

BLOOD（2019）

引用 1|浏览29

暂无评分

摘要

Background: Successful discontinuation of eltrombopag in certain immune thrombocytopenia (ITP) patients after complete response has already been demonstrated. However, the frequency of this phenomenon and type of candidate patients are still matter of discussion. Moreover, possibility of long term discontinuation responses is not clearly established.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要